Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA150027 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:CD133-positive colorectal cancer cells exhibit enhanced tumorigenicity over CD133-negative cells. The CD133+ cells are more interactive with and responsive to their stromal microenvironment because they also express the cognate receptors, such as CXCR4, for ligands produced by their neighboring carcinoma-associated fibroblasts, such as SDF-1 (stromal-derived growth factor). we isolated and separately cultured both the carcinoma cells and CAF from the same patient tumor. Three samples (CD133+, CD133-, Carcinoma associated fibroblasts) in triplicate for a total of 9 samples.
2011-12-01 | E-GEOD-34053 | biostudies-arrayexpress
Project description:CD133-positive colorectal cancer cells exhibit enhanced tumorigenicity over CD133-negative cells. The CD133+ cells are more interactive with and responsive to their stromal microenvironment because they also express the cognate receptors, such as CXCR4, for ligands produced by their neighboring carcinoma-associated fibroblasts, such as SDF-1 (stromal-derived growth factor).
2011-12-01 | GSE34053 | GEO
Project description:Comparison of gene expression between CD133+ and CD133- SW620 human colon cancer cells
| PRJNA131361 | ENA
Project description:Advanced colon cancer is characterized by drug resistance and a poor prognosis. In these patients tumor-propagating cells appear to be largely resistant against various targeted drugs including ErbB-inhibitors. The cell surface antigen prominin-1 (CD133) has recently been identified as a potential marker of colon cancer stem cells. The purpose of this study was to define mRNA expression patterns in CD133+ and CD133- HCT116 cells.
2012-05-22 | GSE38049 | GEO
Project description:CD133 has been widely used for identification and isolation of cancer stem cells in tumors although its role as a marker for cancer stem cell is still controversial . We isolated the CD133+ and CD133- cells from SW620 human colon cancer cell line and compared their biological characteristics, such as tumorigenicity,drug sensitivity, etc. Our study revealed that CD133+ SW620 cells were more tumorigenic and resistant to anti-cancer drugs. Correspondingly, they displayed different gene expression profile. However, it was observed that CD133- cells and CD133+ cells could mutually convert, indicating that CD133 expression was under dynamic and reversible regulations which might impose significant infulence on cells behaviors. Thus, our data challenge the role of CD133 as a marker for cancer stem cell. There are two populations with distinct expression of CD133 in SW620 human colon cancer cell line. Microarray assays were employed to investigate the differentially expressed genes between the two populations, which may possess different tumorigenetic potential and sensitivity to anti-cancer drugs. CD133+ and CD133- cells were isolated from human colon cancer SW620 cell line by magnetic cell sorting system. The clones from sorted CD133+ or CD133- populations were established. Clone cells were expanded and were further purified by using CD133 cell isolation kit before microarray assays.
2010-07-29 | E-GEOD-23295 | biostudies-arrayexpress
Project description:Advanced colon cancer is characterized by drug resistance and a poor prognosis. In these patients tumor-propagating cells appear to be largely resistant against various targeted drugs including ErbB-inhibitors. The cell surface antigen prominin-1 (CD133) has recently been identified as a potential marker of colon cancer stem cells. The purpose of this study was to define mRNA expression patterns in CD133+ and CD133- HCT116 cells. To define mRNA expression patterns in CD133+ and CD133- HCT116 cells, gene array analysis were performed using genome-wide human U133 2.0 plus GeneChips (Affymetrix, Santa Clara, CA, USA). 3 repetitions of CD133+ HCT116 cells and 3 repetitions of CD133- HCT116 cells were performed. Robust Multichip Average (RMA) signal extraction and normalization were performed.
2012-05-21 | E-GEOD-38049 | biostudies-arrayexpress
Project description:CD133 has been widely used for identification and isolation of cancer stem cells in tumors although its role as a marker for cancer stem cell is still controversial . We isolated the CD133+ and CD133- cells from SW620 human colon cancer cell line and compared their biological characteristics, such as tumorigenicity,drug sensitivity, etc. Our study revealed that CD133+ SW620 cells were more tumorigenic and resistant to anti-cancer drugs. Correspondingly, they displayed different gene expression profile. However, it was observed that CD133- cells and CD133+ cells could mutually convert, indicating that CD133 expression was under dynamic and reversible regulations which might impose significant infulence on cells behaviors. Thus, our data challenge the role of CD133 as a marker for cancer stem cell.
2010-07-29 | GSE23295 | GEO
Project description:We identified a novel mechanism by which IL-6/STAT3 signaling up-regulates CD133 expression and promotes HCC progression. STAT3 activation upregulates the expression of CD133 during liver carcinogenesis. Targeting STAT3-mediated CD133 overexpression may represent a promising therapeutic strategy for HCC patients via eradicating the liver tumor microenviornment. To develop novel cancer therapeutic strategies by identification of signaling pathways or biomarkers and understanding their functions on cancer stem cell biology, we determined CD133 expression and STAT3 activation with tumor microenvironment in HCC patient tissues. The relation of STAT3 activation and CD133 expression was investigated by luciferase assay, shRNA knock-down, and chromatin immunoprecipitation assay in HCC cells, and in vivo xenograft model.
2014-08-08 | E-GEOD-60194 | biostudies-arrayexpress
Project description:Metastatic human colon carcinoma cell lines LS411N and SW620 were cultured in the presence of increased concentration of 5-FU. The selected stable cell lines (LS411N-5FU-R and SW620-5FU-R) are CD133+ that are resistant to 5-FU. However, FACS-sorted CD133+ cells from LS411N and SW620 are not resistant to 5-FU, suggesting that only a subset of CD133+ cells are 5-FU-resistant colon cancer stem cells. A global gene expression profiling was performed to identify differentiated expressed genes between LS411N-CD133+ cells and LS411N-5FU-R, and between SW620-CD133+ and SW620-5FU-R cells. These differentially expressed genes are potentially responsible for the colon cancer stem cell phenotypes and chemoresistance.
2016-12-20 | GSE76489 | GEO
Project description:Gene expression profiling of immortalized human mesenchymal stem cells with hTERT/E6/E7 transfected MSCs. hTERT may change gene expression in MSCs. Goal was to determine the gene expressions of immortalized MSCs.
2010-09-25 | GSE24338 | GEO